The IRIS V study: Pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions

Diabetes Technology and Therapeutics

Volumn 10, Issue 3, 2008, Pages 206-212

  Karagiannis, Efstrathios ^a   Pfützner, Andreas ^b,c   Forst, Thomas ^b   Lübben, Georg ^a   Roth, Werner ^b   Grabellus, Martin ^b   Flannery, Manja ^b   Schöndorf, Thomas ^b,d,e  

^a Takeda Pharma GmbH   (Germany)

^b Institute for Clinical Research and Development   (Germany)

^c University of Applied Science   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e IKFE GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BRAIN TUMOR; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE MARKER; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HUMAN; LABORATORY DIAGNOSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; BLOOD PRESSURE; BODY MASS INDEX; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 43549097824     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0244     Document Type: Article

References (41)

1. Kahn CR: Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994;43:1066-1084.
2. Hamman RF: Genetic and environmental determinants of non-insulin- dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287-338.
3. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001;22:36-52.
4. Steinberg HO, Baron AD: Vascular function, insulin resistance and fatty acids. Diabetologia 2002;45:623-634.
5. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 2004;109:II-2-II-10.
6. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
7. Ridker P, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-1959.
8. Tice JA, Browner W, Tracy RP, Cummings SR: The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. Am J Med 2003;114:199-205.
9. Ridker PM: C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003;108:E81-E85.
10. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003;107:R20-R26.
11. Pfützner A, Standl E, Strotmann HJ, Schulze J, Hohberg C, Lübben G, Pahler S, Schöndorf T, Forst T: Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin Chem Lab Med 2006;44:556-560.
12. Pfützner A, Forst T: High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36.
13. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
14. Ridker PM, Hennkens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of coronary disease in women. N Engl J Med 2000;342:836-843.
15. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR: C-reactive protein and risk for incident coronary heart disease in middle aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004;109:837-842.
16. Koenig W, Lowel H, Baumert J, Meisinger C: C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment. Circulation 2004;109:1249-1353.
17. Danesh J, Wheeler JG, Hiorschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulation markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
18. Anan F, Takahashi N, Nakagawa M, Ooie T, Saijkawa T, Yoshimatsu H: High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005;54:552-558.
19. Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, Kim KR, Lee HC: Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract 2005;69:151-159.
20. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T: Anti-Inflammatory effects of pioglitazone and/or Simvastatin in high cardivascular risk patients with elevated his sensitivity C-reactive protein. J Am Coll Cardiol 2007;49:290-297.
21. Forst T, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M: Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism 2007;56:491-496.
22. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-1931.
23. Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, Drexler M, Morcos M, Dänschel W, Borchert M, Pfützner A: Vasoprotective and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008;197:311-317.
24. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.
25. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780.
26. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macro-Vascular Events 04). Stroke 2007;38:865-873.
27. Nesto R: C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004;21:810-817.
28. Goke B; German Pioglitazone Study Group: Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002;1:329-336.
29. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquart R, Edwards G, Johns D, GLAL Study Group: Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28:544-550.
30. Parhofer KG, Otto C, Geiss HC, Laubach E, Goke B: Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - results of a pilot study. Exp Clin Endocrinol Diabetes 2005;113:49-52.
31. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
32. van Wijk JPH, de Koning EJP, Martens EP, Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-1749.
33. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554.
34. Schöndorf T, Forst T, Hohberg C, Pahler S, Lübben G, Link C, Roth W, Pfützner A: The IRIS III-Study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab 2007;9:132-133.
35. Oshinyemi K, Garcia S, Curtis P, Zambanini A, Stewart MW: Evaluation of the effects of rosigltazone combination therapy on ambulatory blood pressure after 6 months; a 12 months substudy of the RECORD trial in people with type 2 diabetes mellitus [abstract]. Diabetologia 2004;47(Suppl 1):A262.
36. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL: Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004;43:48-56.
37. Füllert S, Schneider F, Haak E, Rau H, Badenhoop K, Lübben G, Usadel KH, Konrad T: Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrin Metabol 2002;87:5503-5506.
38. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y: Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005;18:949-957.
39. Pfützner A, Forst T: Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother 2006;7:463-476.
40. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
41. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471. Erratum in: N Engl J Med 2007;357:100.